GS
INTS icon

GTS Securities’s Intensity Therapeutics INTS Stock Holding History

GTS Securities’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-761
Closed -$33.7K – 1407
2024
Q4 		$33.7K Sell
761
-731
-49% -$53.1K ﹤0.01% 1189
2024
Q3 		$142K Buy
+1,492
New +$166K ﹤0.01% 3738

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
OCPWS
One Charles Private Wealth Services Hingham, Massachusetts $434M AUM 22.37% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

GTS Securities's INTS Position: Q1 2025 in Review

GTS Securities sold out of Intensity Therapeutics (INTS) in Q1 2025, closing a stake of 761 shares — an estimated $33.7K sold.

GTS Securities first reported a position in INTS in Q3 2024 and held it in 2 quarters. The position peaked at $142K in Q3 2024. 21 funds tracked by Wall St. Rank hold INTS as of Q1 2025.

  • GTS Securities reported no remaining Intensity Therapeutics position as of Q1 2025 after selling out during the quarter.
  • GTS Securities sold 761 Intensity Therapeutics shares in Q1 2025, an estimated $33.7K.
  • GTS Securities first reported a position in Intensity Therapeutics in Q3 2024 and held it in 2 quarters.
  • GTS Securities's Intensity Therapeutics position peaked at $142K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2025.

Based on GTS Securities's 13F filing for Q1 2025, filed 15 May 2025.